Since the outbreak of COVID-19, researchers in Zhejiang University of Traditional Chinese Medicine have carried out scientific research and achieved phased results in fields of clinical treatment, drug development, vaccine R&D and anti-epidemic materials production with traditional Chinese medicine.

Formulate the plan for the prevention and treatment of COVID-19 with traditional Chinese medicine

When the outbreak started, Professor Wen Chengping, vice-president of Zhejiang University of Traditional Chinese Medicine, led his team to participate in epidemic prevention and control, fought hard in the scientific research of traditional Chinese medicine for the treatment of the disease.

Professor Wen, based on his experience in infectious disease prevention and control, used traditional Chinese medicine in the treatment of COVID-19 and promoted the integration of traditional Chinese and western medicine, which coincided with the idea of the affiliated Hangzhou Xixi Hospital. The Hospital has admitted most patients with mild COVID-19, which provides sufficient conditions for integrated traditional Chinese and western medicine treatment.

Since February 1, Professor Wen's team has cooperated with Xixi Hospital to formulate the clinical treatment plan and scientific research design plan, set up a medical ethics committee, completed the national clinical research registration and adopted the most rigorous RCT research. Through the analysis of previous kinds of literature and clinical data, it is found that patients with spleen-lung deficiency syndrome are more likely to suffer severe pneumonia after being infected with the COVID-19 virus. The "Peiyuan Xuanhua Jiedu Recipe" has been adopted for targeted treatment, and the overall clinical treatment has met people’s expectations, and further in-depth research is currently being done.

To relieve the physical discomfort of patients caused by a large amount of medication and infusion, Ding Xinghong, a team member, worked with Shou Dan from Zhejiang Institute of Traditional Chinese Medicine, to develop two kinds of patches, namely the "spleen-activating and dampness-eliminating patch" for Shenque acupoint and the "lung-dispersing and interpretation patch" for Shanzhong and Dazhui acupoints. The two patches were later sent to Huanggang, Wuhan, and Lishui for frontline treatment.

Commissioned to develop preparations for Wuhan

Zhejiang University of Traditional Chinese Medicine and Guangdong Molecular Biology Co., Ltd. jointly set up a Research Center of Component Traditional Chinese Medicine Preparation, which has been commissioned by the Wuhan side to develop preparations twice. The first orders (4,000 copies) of the prescription for the prevention and treatment of COVID-19 arrived in Wuhan on February 19 and were then distributed to Wuhan Union Hospital, Tongji Hospital, Zhongnan Hospital of Wuhan University and the Central Hospital of Wuhan. They were put into clinical practice and achieved good clinical results.

Zhejiang University of Traditional Chinese Medicine recently took on the task of developing the preparation for patients during the recovery from COVID-19, and the development is currently in the process research stage. After the process is determined, the pilot-scale amplification experiment will be carried out to achieve the expected effect before mass production.

新冠肺炎疫情发生以来，浙江中医药大学坚持以中医中药为优势，一大批科研工作者们开展科研攻关，在临床治疗、药物研制、疫苗研发、抗疫物资等各领域，取得了阶段性成果，拿出了不少硬核产品。

制定中医药防治新冠肺炎方案

疫情警报拉响，浙江中医药大学副校长温成平教授第一时间带领团队投身疫情防控工作，奋战科研，坚持发挥中医药在新冠肺炎救治的作用。

温教授结合过去传染病防控经验，想到将中医药介入新冠肺炎治疗、推动中西医结合防治，这与该校附属杭州西溪医院的想法不谋而合。西溪医院收治了杭州市大部分新冠肺炎轻症患者，为开展新冠肺炎中西医结合治疗提供了充分条件。

自2月1日起，温教授团队便与西溪医院合作，研究制定临床治疗方案与科研设计方案，组建医学伦理委员会，完成国家临床研究注册，最后采取最严谨的RCT研究。通过前期文献和临床资料分析，发现脾肺两虚症人群感染新冠病毒后，更容易转化为重型肺炎，已采用“培元宣化解毒方”予以针对性治疗，临床总体治疗符合预期，目前正在做进一步深入研究。

为缓解患者因大量服药、输液产生的身体不适，团队的丁兴红老师联合浙江中医药研究院的寿旦老师，临时研发了两种贴剂，分别是可贴于神阙穴的“运脾化湿贴”和可贴于膻中穴、大椎穴的“宣肺解读贴”。这两种贴剂后来也被寄往武汉黄冈和浙江丽水，用于一线救治。

受托研制制剂供应武汉

浙江中医药大学与广东分子态生物股份有限公司联合成立的组分中药（中药复方现代化）制剂研究中心，先后两次接受武汉方委托制剂研制。疫毒闭肺方首批订单（4000人份）已于2月19日运抵武汉，分发到武汉协和医院、同济医院、中南医院和中心医院等多家医院，投入临床，取得了较好的临床效果。

浙江中医药大学最新接到的新冠肺炎恢复期制剂研制任务，目前正处在工艺研究阶段。在工艺确定后，还需在中试规模下进行放大实验，达到预期效果后再批量生产。